AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15029-

  Hui, Daniel J ^a   Edmonson, Shyrie C ^a,b   Podsakoff, Gregory M ^a   Pien, Gary C ^a   Ivanciu, Lacramioara ^a,c   Camire, Rodney M ^c   Ertl, Hildegund ^d   Mingozzi, Federico ^a   High, Katherine A ^a,b,c   Basner Tschakarjan, Etiena ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; BLOOD CLOTTING FACTOR 9; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B51 ANTIGEN; HLA B7 ANTIGEN; HLA B8 ANTIGEN; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN VP1; TUMOR NECROSIS FACTOR; HLA ANTIGEN; HLA B 0702 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN;

ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 8; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SPECIFICITY; CELLULAR IMMUNITY; CHILD; CONSERVED SEQUENCE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; SPLEEN CELL; SPLENECTOMY; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; CYTOTOXICITY; HLA TYPING; LIVER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; SPLEEN;

EID: 84945932371     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.29     Document Type: Article

References (41)

1. 1 Podsakoff, G, Wong, KK Jr, Chatterjee, S, Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 68 (1994), 5656–5666.
2. 2 Fields, PA, Kowalczyk, DW, Arruda, VR, Armstrong, E, McCleland, ML, Hagstrom, JN, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 1 (2000), 225–235.
3. 3 Jooss, K, Yang, Y, Fisher, KJ, Wilson, JM, Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72 (1998), 4212–4223.
4. 4 Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y, et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15 (2007), 792–800.
5. 5 Zaiss, AK, Liu, Q, Bowen, GP, Wong, NC, Bartlett, JS, Muruve, DA, Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76 (2002), 4580–4590.
6. 6 Warrington, KH Jr, Herzog, RW, Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119 (2006), 571–603.
7. 7 Büning, H, Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med 5 (2013), 1–3.
8. 8 Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 12 (2006), 342–347.
9. 9 Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13 (2007), 419–422.
10. 10 Brantly, ML, Chulay, JD, Wang, L, Mueller, C, Humphries, M, Spencer, LT, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 106 (2009), 16363–16368.
11. 11 Jaski, BE, Jessup, ML, Mancini, DM, Cappola, TP, Pauly, DF, Greenberg, B, et al., Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase ½ clinical trial. J Card Fail 15 (2009), 171–181.
12. 12 Mendell, JR, Rodino-Klapac, LR, Rosales-Quintero, X, Kota, J, Coley, BD, Galloway, G, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 66 (2009), 290–297.
13. 13 Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, Edmonson, SA, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114 (2009), 2077–2086.
14. 14 Mendell, JR, Rodino-Klapac, LR, Rosales, XQ, Coley, BD, Galloway, G, Lewis, S, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68 (2010), 629–638.
15. 15 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
16. 16 Finn, JD, Hui, D, Downey, HD, Dunn, D, Pien, GC, Mingozzi, F, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther 18 (2010), 135–142.
17. 17 Pien, GC, Basner-Tschakarjan, E, Hui, DJ, Mentlik, AN, Finn, JD, Hasbrouck, NC, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 119 (2009), 1688–1695.
18. 18 Blacklow, NR, Hoggan, MD, Rowe, WP, Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 40 (1968), 319–327.
19. 19 Calcedo, R, Vandenberghe, LH, Gao, G, Lin, J, Wilson, JM, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199 (2009), 381–390.
20. 20 Veron, P, Leborgne, C, Monteilhet, V, Boutin, S, Martin, S, Moullier, P, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol 188 (2012), 6418–6424.
21. 21 Chirmule, N, Propert, K, Magosin, S, Qian, Y, Qian, R, Wilson, J, Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6 (1999), 1574–1583.
22. 22 Ventura, C, Bisceglia, H, Girerd-Chambaz, Y, Burdin, N, Chaux, P, HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals. J Clin Immunol 32 (2012), 1305–1316.
23. 23 Reche, PA, Glutting, JP, Reinherz, EL, Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 63 (2002), 701–709.
24. 24 Buchli, R, VanGundy, RS, Hickman-Miller, HD, Giberson, CF, Bardet, W, Hildebrand, WH, Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201–a new tool for epitope discovery. Biochemistry 44 (2005), 12491–12507.
25. 25 van der Burg, SH, Visseren, MJ, Brandt, RM, Kast, WM, Melief, CJ, Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156 (1996), 3308–3314.
26. 26 Li, C, Hirsch, M, Asokan, A, Zeithaml, B, Ma, H, Kafri, T, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 81 (2007), 7540–7547.
27. 27 Wang, L, Figueredo, J, Calcedo, R, Lin, J, Wilson, JM, Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 18 (2007), 185–194.
28. 28 Janetzki, S, Panageas, KS, Ben-Porat, L, Boyer, J, Britten, CM, Clay, TM, et al., Elispot Proficiency Panel of the CVC Immune Assay Working Group. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57 (2008), 303–315.
29. 29 Calis, JJ, Maybeno, M, Greenbaum, JA, Weiskopf, D, De Silva, AD, Sette, A, et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol, 9, 2013, e1003266.
30. 30 Ellis, BL, Hirsch, ML, Barker, JC, Connelly, JP, Steininger, RJ 3rd, Porteus, MH, A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J, 10, 2013, 74.
31. 31 Wu, TL, Li, H, Faust, SM, Chi, E, Zhou, S, Wright, F, et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors’ genome. Mol Ther 22 (2014), 42–51.
32. 32 Altman, JD, Moss, PA, Goulder, PJ, Barouch, DH, McHeyzer-Williams, MG, Bell, JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996), 94–96.
33. 33 Aslanidi, GV, Rivers, AE, Ortiz, L, Song, L, Ling, C, Govindasamy, L, et al. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?. PLoS One, 8, 2013, e59142.
34. 34 Jones, TD, Phillips, WJ, Smith, BJ, Bamford, CA, Nayee, PD, Baglin, TP, et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 3 (2005), 991–1000.
35. 35 Yeung, VP, Chang, J, Miller, J, Barnett, C, Stickler, M, Harding, FA, Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172 (2004), 6658–6665.
36. 36 Martino, AT, Basner-Tschakarjan, E, Markusic, DM, Finn, JD, Hinderer, C, Zhou, S, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121 (2013), 2224–2233.
37. 37 Andreansky, SS, Stambas, J, Thomas, PG, Xie, W, Webby, RJ, Doherty, PC, Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses. J Virol 79 (2005), 4329–4339.
38. 38 Matsushita, T, Elliger, S, Elliger, C, Podsakoff, G, Villarreal, L, Kurtzman, GJ, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5 (1998), 938–945.
39. 39 Ayuso, E, Mingozzi, F, Montane, J, Leon, X, Anguela, XM, Haurigot, V, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 17 (2010), 503–510.
40. 40 Betts, MR, Nason, MC, West, SM, De Rosa, SC, Migueles, SA, Abraham, J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006), 4781–4789.
41. 41 Rammensee, H, Bachmann, J, Emmerich, NP, Bachor, OA, Stevanović, S, SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999), 213–219.